Retatrutide Side Effects: What Clinical Trials Show So Far

What Is Retatrutide and Why Does It Matter?

Retatrutide (LY3437943) is a single peptide that activates three hormone receptors: GLP-1, GIP, and glucagon. Most approved drugs in this class target one or two. Zepbound (tirzepatide), for example, hits GLP-1 and GIP. Adding glucagon receptor activation increases energy expenditure and promotes liver fat reduction. In a phase 1b trial of 72 people with type 2 diabetes, retatrutide showed a half-life of approximately 6 days, supporting once-weekly injection.

Gastrointestinal Side Effects Are the Most Common

Nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse events across all retatrutide trials. In the phase 2 obesity trial of 338 adults, these GI effects were dose-related and mostly mild to moderate. They occurred primarily during early dose escalation and were partially mitigated by starting at 2 mg rather than 4 mg. A lower starting dose gave the body more time to adjust.

Discontinuation Rates and Tolerability

GI side effects led roughly 10 to 17% of retatrutide-treated participants to stop treatment in phase 2, compared to 0 to 4% on placebo and about 2% on dulaglutide. A systematic review of 640 patients confirmed that non-severe gastrointestinal and hypersensitivity events were more common with retatrutide than placebo. These rates are higher than single-target GLP-1 drugs, which is expected given the triple-receptor mechanism.

Heart Rate Increases Are Dose-Dependent

Retatrutide raises resting heart rate in a dose-dependent pattern, peaking around week 24 and partially declining afterward. One expert review noted increases of up to 6.7 beats per minute at the highest doses, along with mild to moderate cardiac arrhythmias. No major adverse cardiovascular events were significantly increased versus placebo in available data, but follow-up has been short. Long-term cardiovascular outcome trials are still needed.

Liver Fat Reduction, Not Liver Harm

Retatrutide appears to benefit the liver rather than harm it. The phase 2 type 2 diabetes trial showed an 82% reduction in hepatic steatosis (liver fat). Meta-analyses found no significant increase in hepatic or biliary disease, and no clear signal for pancreatitis. Liver enzymes (AST, ALT, amylase, lipase) showed no consistent clinically important elevations in pooled data. This liver effect is partly attributed to glucagon receptor activation.

How Side Effects Compare to Other GLP-1 Drugs

Network meta-analyses show retatrutide carries a higher overall adverse event risk than GLP-1 monotherapy or dual agonists, driven primarily by GI events and vomiting. Cholelithiasis (gallstones) risk may also be higher. However, serious adverse events and deaths remained rare and similar to placebo. A Bayesian NMA of 29,506 adults found retatrutide had the highest efficacy for weight loss but also the highest adverse event risk among all comparators.

Weight Loss Results That Explain the Interest

The side effect profile matters in context. At 48 weeks, the 12 mg retatrutide group lost a mean of 24.2% of body weight, with 83% achieving at least 15% weight loss. A systematic review across 878 patients found mean body weight reductions of 14.33%, plus significant decreases in waist circumference (10.51 cm), fasting glucose, and blood pressure. These results surpass any single approved GLP-1 drug.

What to Know While Retatrutide Is Still in Trials

Phase 3 trials (the TRIUMPH program) are currently underway, and results will clarify long-term safety in larger, more diverse populations. Retatrutide is not available by prescription today. If you want to start GLP-1 therapy now, Zepbound (tirzepatide) is FDA-approved and produced up to 17.8% weight loss in clinical trials as a dual GLP-1/GIP agonist. Instalab offers physician evaluation and a Zepbound prescription for $99.